Literature DB >> 33494095

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis.

Bryan A Johnson1, Xuping Xie2, Adam L Bailey3, Birte Kalveram4, Kumari G Lokugamage1, Antonio Muruato1, Jing Zou2, Xianwen Zhang2, Terry Juelich4, Jennifer K Smith4, Lihong Zhang4, Nathen Bopp4, Craig Schindewolf1, Michelle Vu1, Abigail Vanderheiden5,6, Emma S Winkler3,7, Daniele Swetnam2, Jessica A Plante1, Patricia Aguilar4, Kenneth S Plante1, Vsevolod Popov4, Benhur Lee8, Scott C Weaver1,9, Mehul S Suthar5,6,10, Andrew L Routh2, Ping Ren4, Zhiqiang Ku11, Zhiqiang An11, Kari Debbink12, Michael S Diamond3,7,13, Pei-Yong Shi2,9, Alexander N Freiberg4,9, Vineet D Menachery14,15.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-a new coronavirus that has led to a worldwide pandemic1-has a furin cleavage site (PRRAR) in its spike protein that is absent in other group-2B coronaviruses2. To explore whether the furin cleavage site contributes to infection and pathogenesis in this virus, we generated a mutant SARS-CoV-2 that lacks the furin cleavage site (ΔPRRA). Here we report that replicates of ΔPRRA SARS-CoV-2 had faster kinetics, improved fitness in Vero E6 cells and reduced spike protein processing, as compared to parental SARS-CoV-2. However, the ΔPRRA mutant had reduced replication in a human respiratory cell line and was attenuated in both hamster and K18-hACE2 transgenic mouse models of SARS-CoV-2 pathogenesis. Despite reduced disease, the ΔPRRA mutant conferred protection against rechallenge with the parental SARS-CoV-2. Importantly, the neutralization values of sera from patients with coronavirus disease 2019 (COVID-19) and monoclonal antibodies against the receptor-binding domain of SARS-CoV-2 were lower against the ΔPRRA mutant than against parental SARS-CoV-2, probably owing to an increased ratio of particles to plaque-forming units in infections with the former. Together, our results demonstrate a critical role for the furin cleavage site in infection with SARS-CoV-2 and highlight the importance of this site for evaluating the neutralization activities of antibodies.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33494095      PMCID: PMC8175039          DOI: 10.1038/s41586-021-03237-4

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  224 in total

1.  HLA class I-associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children.

Authors:  Rebecca A Porritt; Lisa Paschold; Magali Noval Rivas; Mary Hongying Cheng; Lael M Yonker; Harsha Chandnani; Merrick Lopez; Donjete Simnica; Christoph Schultheiß; Chintda Santiskulvong; Jennifer Van Eyk; John K McCormick; Alessio Fasano; Ivet Bahar; Mascha Binder; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 2.  Diversity and evolution of the animal virome.

Authors:  Erin Harvey; Edward C Holmes
Journal:  Nat Rev Microbiol       Date:  2022-01-04       Impact factor: 60.633

Review 3.  The emergence, genomic diversity and global spread of SARS-CoV-2.

Authors:  Juan Li; Shengjie Lai; George F Gao; Weifeng Shi
Journal:  Nature       Date:  2021-12-08       Impact factor: 49.962

4.  Avoiding culture shock with the SARS-CoV-2 spike protein.

Authors:  Benjamin G Hale
Journal:  Elife       Date:  2021-05-18       Impact factor: 8.140

Review 5.  HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens.

Authors:  Will Fischer; Elena E Giorgi; Srirupa Chakraborty; Kien Nguyen; Tanmoy Bhattacharya; James Theiler; Pablo A Goloboff; Hyejin Yoon; Werner Abfalterer; Brian T Foley; Houriiyah Tegally; James Emmanuel San; Tulio de Oliveira; Sandrasegaram Gnanakaran; Bette Korber
Journal:  Cell Host Microbe       Date:  2021-06-03       Impact factor: 31.316

6.  In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.

Authors:  Michael Diamond; Rita Chen; Emma Winkler; James Case; Ishmael Aziati; Traci Bricker; Astha Joshi; Tamarand Darling; Baoling Ying; John Errico; Swathi Shrihari; Laura VanBlargan; Xuping Xie; Pavlo Gilchuk; Seth Zost; Lindsay Droit; Zhuoming Liu; Spencer Stumpf; David Wang; Scott Handley; W Stine; Pei-Yong Shi; Miguel Garcia-Knight; Raul Andino; Charles Chiu; Ali Ellebedy; Daved Fremont; Sean Whelan; James Crowe; Lisa Purcell; Davide Corti; Andrianus Boon
Journal:  Res Sq       Date:  2021-04-23

Review 7.  Why All the Fury over Furin?

Authors:  Essam Eldin A Osman; Alnawaz Rehemtulla; Nouri Neamati
Journal:  J Med Chem       Date:  2021-08-02       Impact factor: 7.446

8.  TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2.

Authors:  Joseph D Trimarco; Brook E Heaton; Ryan R Chaparian; Kaitlyn N Burke; Raquel A Binder; Gregory C Gray; Clare M Smith; Vineet D Menachery; Nicholas S Heaton
Journal:  PLoS Pathog       Date:  2021-05-27       Impact factor: 6.823

Review 9.  Cell entry by SARS-CoV-2.

Authors:  Ruchao Peng; Lian-Ao Wu; Qingling Wang; Jianxun Qi; George Fu Gao
Journal:  Trends Biochem Sci       Date:  2021-06-07       Impact factor: 13.807

10.  Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection.

Authors:  Nidhi Shukla; Sarah M Roelle; Vinicius G Suzart; Anna M Bruchez; Kenneth A Matreyek
Journal:  PLoS Pathog       Date:  2021-07-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.